Cargando…

Sulfasalazine: a risk factor for severe COVID-19?

Detalles Bibliográficos
Autores principales:	Konig, Maximilian F, Grzes, Katarzyna M, Robinson, Philip C, Pearce, Edward J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923673/ https://www.ncbi.nlm.nih.gov/pubmed/35310293 http://dx.doi.org/10.1016/S2665-9913(22)00067-4

Ejemplares similares

Patients with gout: an under-recognised group at high risk of COVID-19
por: Dalbeth, Nicola, et al.
Publicado: (2021)

Social vulnerability as a risk factor for death due to severe paediatric COVID-19
por: Mujica, Oscar J, et al.
Publicado: (2021)

What does endemic COVID-19 mean for the future of rituximab?
por: Liew, David F L, et al.
Publicado: (2022)

Clinical course and mortality risk of severe COVID-19
por: Weiss, Paul, et al.
Publicado: (2020)

Are women with asthma at increased risk for severe COVID-19?
por: Fernando, Mario, et al.
Publicado: (2021)

Preventive medicine in rheumatology: COVID-19 and its lessons for better health outcomes
por: Liew, David F L, et al.
Publicado: (2022)

Divergent effects of acute versus chronic glucocorticoids in COVID-19
por: Robinson, Philip C, et al.
Publicado: (2021)

COVID-19 severity and obesity: are MAIT cells a factor?
por: McCarthy, Cormac, et al.
Publicado: (2021)

The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic
por: Robinson, Philip C., et al.
Publicado: (2020)

Racial and ethnic differences in COVID-19 outcomes: a call to action
por: Robinson, Philip C, et al.
Publicado: (2022)

Changing COVID-19 outcomes in patients with rheumatic disease—are we really getting better at this?
por: Gianfrancesco, Milena A, et al.
Publicado: (2021)

Azithromycin for severe COVID-19
por: Oldenburg, Catherine E, et al.
Publicado: (2020)

Increased risk of severe COVID-19 outcomes in patients with rheumatoid arthritis and interstitial lung disease
por: Kelly, Clive
Publicado: (2022)

Mounting evidence of impaired viral control in severe COVID-19
por: Bermejo-Martin, Jesus F, et al.
Publicado: (2021)

Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment
por: Robinson, Philip C, et al.
Publicado: (2020)

Severe COVID-19 pneumonitis and timing of birth in women
por: Calvert, Clara, et al.
Publicado: (2023)

Observational research on severe COVID-19 in diabetes
por: Stehouwer, Coen D A
Publicado: (2021)

Severe mental illness and European COVID-19 vaccination strategies
por: De Picker, Livia J, et al.
Publicado: (2021)

Comparative treatment of Sulfasalazine+Ezetimibe combination and Sulfasalazine in a rat model with induced colitis
por: Jaafar, Farrah Rasool, et al.
Publicado: (2023)

Epidemiology of severe COVID-19 from South Africa
por: Madhi, Shabir A, et al.
Publicado: (2021)

The effects of antihypertensive medications on severity and outcomes of COVID19
por: Agirbasli, Mehmet
Publicado: (2022)

Severe COVID-19 in the young and healthy: monogenic inborn errors of immunity?
por: Zhang, Shen-Ying, et al.
Publicado: (2020)

A role for interleukin-1 receptor antagonism in severe COVID-19?
por: Tattersall, Rachel S, et al.
Publicado: (2021)

Treatment for severe acute respiratory distress syndrome from COVID-19
por: Matthay, Michael A, et al.
Publicado: (2020)

COVID-19 vaccination is effective at preventing severe illness and complications during pregnancy
por: Ellington, Sascha, et al.
Publicado: (2023)

Who, what, and when—effective therapy for severe COVID-19
por: Kelmenson, Daniel A, et al.
Publicado: (2022)

Severe COVID-19 and preexisting hypertension: a matter of age?
por: Yamazaki, Osamu, et al.
Publicado: (2022)

Risk stratification of patients with COVID-19 in the community
por: Knight, Stephen R, et al.
Publicado: (2022)

Circulating levels of soluble Dipeptidylpeptidase-4 are reduced in human subjects hospitalized for severe COVID-19 infections
por: Schlicht, Kristina, et al.
Publicado: (2020)

Covid-19 and breastfeeding: what’s the risk?
por: Hand, Ivan L., et al.
Publicado: (2020)

COVID-19: risk for cytokine targeting in chronic inflammatory diseases?
por: Schett, Georg, et al.
Publicado: (2020)

Will helminth co-infection modulate COVID-19 severity in endemic regions?
por: Bradbury, Richard S., et al.
Publicado: (2020)

Severe breakthrough COVID-19 infections in Scotland—implications for immunisation programmes
por: Leshem, Eyal, et al.
Publicado: (2021)

Baricitinib for patients with severe COVID-19—time to change the standard of care?
por: Supady, Alexander, et al.
Publicado: (2022)

Stimulating severe COVID-19: the potential role of GM-CSF antagonism
por: Leavis, Helen L, et al.
Publicado: (2022)

Closing COVID-19 mortality, vaccination, and evidence gaps for those with severe mental illness
por: De Picker, Livia J
Publicado: (2021)

Evaluating COVID-19 vaccines in the real world
por: Mills, Edward J, et al.
Publicado: (2022)

Suicide risk and prevention during the COVID-19 pandemic
por: Gunnell, David, et al.
Publicado: (2020)

Case report: Sulfasalazine-induced hypersensitivity
por: Kuchinskaya, Ekaterina M., et al.
Publicado: (2023)

Long COVID — metabolic risk factors and novel therapeutic management
por: Khunti, Kamlesh, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d415cgkadtfac679vkhvcn7p4e